Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)

Launched by CEDARS-SINAI MEDICAL CENTER · May 21, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating a condition called Small Intestinal Bacterial Overgrowth (SIBO) in patients with pancreatic cancer, specifically pancreatic adenocarcinoma (PDAC). The study aims to find out how common SIBO is among these patients and whether it is linked to weight loss, which is a common issue for those with this type of cancer. To participate, individuals must be 18 years or older, have a confirmed diagnosis of pancreatic adenocarcinoma, and have experienced weight loss. The trial is open to everyone, regardless of gender.

Participants in this study will undergo a simple test called a Lactulose Hydrogen Breath Test to check for SIBO. The researchers are looking to enroll 100 patients who meet the criteria, and the trial is currently recruiting participants. It’s important to note that individuals who are pregnant, under 18, or have received treatment for SIBO in the last three months cannot participate. By joining this study, participants will help researchers better understand the relationship between SIBO and weight loss in pancreatic cancer, potentially leading to improved care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men, Women, and all genders
• • Individuals 18 years old or older are included.
• • Patients of the study investigators and team members
• • Diagnosis of pancreatic ductal adenocarcinoma
• • All subjects must consent to this study
• • Clinically diagnosed weight loss
• Exclusion Criteria:
• • Minors
• • Pregnant Women
• • Any records flagged "break the glass" or "research opt out."
• • Patients who have received treatment for SIBO in the past 3 months